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Abstract
Background: Blockade of the PD-1/PD-L1 immune checkpoint pathway is emerging as a promising immunotherapeutic
approach for the management and treatment of head and neck cancer patients who do not respond to 1st/2nd line
therapy. However, as checkpoint inhibitors are cost intensive, identifying patients who would most likely benefit
from anti PD-L1 therapy is required. Developing a non-invasive technique would be of major benefit to the
patient and to the health care system.
Case presentation: We report the case of a 56 year old man affected by a supraglottic squamous cell carcinoma
(SCC). A CT scan showed a 20 mm right jugulodigastric node and suspicious lung lesions. The lung lesion was
biopsied and confirmed to be consistent with SCC. The patient was offered palliative chemotherapy. At the time
of presentation, a blood sample was taken for circulating tumour cell (CTC) analysis. The dissemination of cancer
was confirmed by the detection of CTCs in the peripheral blood of the patient, measured by the CellSearch
System (Janssen Diagnostics). Using marker-independent, low-shear spiral microfluidic technology combined with
immunocytochemistry, CTC clusters were found in this patient at the same time point, expressing PD-L1.
Conclusion: This report highlights the potential use of CTCs to identify patients which might respond to anti
PD-L1 therapy.
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Background
Head and neck cancer (HNC) patients often present
with advanced metastatic disease. Whilst there have
been improvements in the management of locoregional
disease, distant metastatic spread remains a challenge in
the field [1–3]. Palliative chemotherapy is platinum
based and for patients who progress after first line treat-
ment or are refractory, therapeutic options are limited.
Numerous agents including cetuximab, paclitaxel, gem-
citabine and docetaxel have been assessed prospectively
in the treatment of platinum refractory patients and the
time to progression ranged from 2 to 6 months [4].
These systemic treatments produce a significant degree
of morbidity and new therapeutic options are therefore a
need in these patients. Once there is an established role
in metastatic disease, translation into the curative setting
is appropriate.
The programmed cell death-1/programmed cell death-
1 ligand (PD-1/PD-L1) pathway has shown to play a cru-
cial role in tumour immune invasion. Recent literature
suggests that PD-L1 over expression in solid tumour
types has shown direct tumour protection. Recent stud-
ies have shown that antibodies targeting PD-1/PD-L1
have significant anti-tumour activity with a much lower
toxicity profile and are currently being investigated in a
number of tumour types [5, 6]. Pembrolizumab (previ-
ously MK-3475) is a highly selective, humanized igG4
(kappa) isotype monoclonal antibody designed to block
PD-1 interacting with ligands, PD-L1 and PD-L2,
thereby allowing the immune system to target and des-
troy the tumour. Pembrolizumab was the first anti PD-1
antibody to be approved by the FDA [6].
In the 2014, American Society of Clinical Oncology
(ASCO) meeting, it was reported that in a majority
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(77.9%) of pre-treated HNSCC patients, PD-L1 is
expressed in the tumour, defined by ≥1% stained cells
in the tumour microenvironment [7]. In the Keynote
012 trial presented at ASCO 2015, tumour shrinkage
was found in 57% of patients, and overall response of
24.8%, comprised of 26.3% in HPV-negative and
20.6% HPV-positive patients [5, 8]. The Keynote 012
study indicated that Pembrolizumab was twice as
effective as cetuximab with durable responses in pa-
tients which has not been seen previously in HNC.
Pembrolizumab was also well tolerated in these
patients with low rates of adverse effects. 86% of the
responsive patients enrolled in the Keynote 012 study
continued to receive treatment highlighting the ac-
ceptable safety profile [7, 8].
Metastatic sites have shown unique genomic alter-
ations, which can be quite different from the primary
site [9, 10]. Invasive procedures are currently required
to biopsy these metastatic sites, some of which may be
inaccessible. Other studies have shown that these biop-
sies may not be representative of all of the metastatic
disease [11]. An alternative approach used in other
cancer types is the analysis of blood samples for circu-
lating tumour cells (CTCs) as a form of “liquid biopsy”
[12–14]. These rare tumour cells in circulation repre-
sent the “transient” cancer cell population that have
the propensity to metastasize to distant sites. Recent
reports have shown how CTCs may provide comple-
mentary information to identify candidate therapeutic
targets and drug resistance mechanisms [9, 12, 15].
Moreover, CTCs represent cells from the primary and
metastatic sites, thereby possibly providing a more
comprehensive overview of the tumour burden of an
individual patient. CTCs in the blood of HNC patients
provide an opportunity to identify patients “at-risk” of
developing overt metastasis in due course. More
importantly, the analysis of these metastatic seeds in
circulation may reveal important information for sys-
temic therapy targeting metastatic disease [9]. CTCs
are currently being investigated as predictive bio-
markers for HER-2 targeted therapies [16]. A similar
strategy could be used for immune checkpoint block-
ade therapies such as PD-L1.
We report the case study of a 56 year old man who
had been diagnosed with a supraglottic SCC and
treated with chemoradiotherapy. The patient was
assessed for CTCs by the FDA-approved CellSearch
(Janssen Diagnostics) and spiral microfluidics plat-
form. Single CTCs were detected by both platforms.
Using the spiral approach, CTC clusters were identi-
fied expressing PD-L1. We propose the notion that
CTC PD-L1 assessment may be an avenue to identify
patients who would be suitable candidates for anti-
PDL1 therapy.
Case presentation
A 56 year old Caucasian male with a background history
of Crohn’s disease, treated with azathioprine, presented
at the end of 2013 with a supraglottic T3N2b squamous
cell carcinoma which was treated with upfront chemora-
diotherapy, utilising Cisplatin. In October 2014, a CT
scan showed a 20 mm right jugulodigastric node. Lung
lesions were observed which were queried to be fungal/
distant metastasis by the MDT clinic. Biopsied specimen
of the lung lesions confirmed moderately differentiated
SCC. Progressive disease to the lungs and pelvic bone
were observed whilst on Taxol and Carboplatin, given
weekly. Having limited options, a trial of infusional 5-FU
(fluorouracil) was given at the end of 2015. The patient
died in February 2016.
Chest X-ray
Nodules were projected over the left infrahilar region
and within the right upper lobe suspicious for SCC me-
tastasis (Fig. 1).
CTC assessment by CellSearch
The Patient presented with CellSearch-positive CTCs
(2CTCs/7.5 ml) in circulation at time of presentation to
clinic (Fig. 2).
CTC assessment by spiral technology
The Patient presented with 4 single CTCs
(EGFR + CK + DAPI + CD45-) (Fig. 3) and 2 CTC clus-
ters (EGFR + PDL1 + DAPI+) (Fig. 4). The CTC clus-
ters showed a PD-L1 mean intensity in the mid to high
Fig. 1 Chest CT scan of Patient showing lung lesion indicated by
arrow. The lung biopsy was consistent with moderately
differentiated SCC
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dynamic range, determined using a panel of known
HNC cell lines (Fig. 5).
Immunoassay
The antibody against PD-L1 showed a relatively high
mean intensity for (FaDu-Additional file 1: Fig. S1),
medium (SCC25, CAL27), low (SCC15, 93-VU-147 T)
and a negative control (K562 – Additional file 1: Fig. S2).
PD-L1 staining of the CTC channel with spiked SCC-15
cells (Additional file 1: Fig. S3) and waste channel showing
the bulk of leukocytes (Additional file 1: Fig. S4).
Isolation of CTCs by CellSearch
7.5 mL of whole blood collected in CellSave blood col-
lection tubes (Janssen Diagnostics) was mixed with
6.5 ml of CellTracks™ buffer and centrifuged at 800 x g
for 10 mins. The sample was placed on the AutoPrep™
system and the protocol followed as per manufacturer’s
instructions. The system uses a positive selection enrich-
ment based on EpCAM antibodies and characterizes the
selected cells for pan-cytokeratin (pan-CK), CD45 and
DAPI staining. A CTC was determined based on the fol-
lowing parameters: positive for EpCAM, pan-CK, DAPI,
at least a diameter of 4x4μm and negative for CD45
(common leukocyte marker). The results were reported
as the number of CTCs/7.5 ml whole blood.
Enrichment of CTCs by spiral microfluidics technology
8 mL of whole blood was collected in EDTA tubes (BD-
Plymouth, UK). To reduce the cellular components pass-
ing through the spiral chip, a red blood cell (RBC) lysis
was performed. Briefly, post RBC lysis (Astral Scientifix),
the sample was centrifuged and the pellet resuspended
in 10 mL of sheath buffer (1xPBS, 2 mM EDTA, 0.5%
BSA). Tygon® tubing was inserted into the inlet/outlets
of the spiral chip, and the inlet tubing connected to a
syringe pump. The spiral chip was fixed into position on
a phase contrast microscope (Olympus, IX71). The out-
let tubing was connected to sterile 15 mL BD falcon col-
lection tubes. To run the patient sample, the sample was
carefully loaded into a 10 ml syringe and pumped
through the spiral chip at a flow rate of 1.7 ml/min [17].
The outputs were collected and spun down at 300 x g
for 5 mins. The enriched cell suspension was cytospun
onto 2 glass slides using the Cytospin™ 4 Cytocentrifuge
(ThermoScientific, USA). The presence of CTCs was de-
termined by immunofluorescent staining.
Development of an immunoassay for PD-L1
Five head and neck cell lines were used to develop a dy-
namic range of PD-L1 expression. FaDu (ATCC®HTB43™),
CAL27 (ATCC®CRL2095™), SCC25 (ATCC®CRL-1628™)
were from the American Type Culture Collection
(ATCC™). SCC15 (ATCC®CRL-1623™) a generous gift
from Dr. Glen Boyle (QIMR, Brisbane) and 93-VU-147 T
(CVCL_L895) (HPV-positive) cell line from Dr. Johan de
Winter (VU Medical Center, Netherlands). The human
chronic myelogenous leukemia K562 (ATCC®CCL-243)
cells were used as a negative control (gift from Prof Maher
Gandhi, UQDI, Brisbane). Briefly, cytospins (Cytospin™
Cytocentrifuge, USA) were prepared using aliquots of
1000 cells/slide by centrifugation at 300 x g for 5 mins.
Fig. 2 Patient presented with CellSearch-positive CTCs in circulation at time of presentation to clinic. CTCs: EpCAM + CK + DAPI + CD45-,
Leukocytes: CD45 + DAPI+
Fig. 3 Single CTCs detected after enrichment using spiral microfluidics. Immunofluorescent staining for (a) DAPI (b) Cytokeratin (c) EGFR (d)
Composite EGFR/DAPI (e) CD45. CTCs: EGFR + CK + DAPI + CD45-. White blood cells: CD45 + DAPI+. Scale bar represents 50 μm
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The slides were stained with PD-L1 as per the immuno-
cytochemistry protocol below.
Immunocytochemistry
Briefly, the initial sample was stained using the Cell-
Search antibody cocktail (Janssen Diagnostics) and
anti-EGFR antibody (AY13, Biolegend, San Diego) as
previously described [18–20]. A further slide was fixed
with 4% formaldehyde for 10 mins, permeabilized with
0.2% Triton X-100 for 5 mins and blocked with 10%
fetal-bovine serum in 0.1% PBS-Tween for 1 h at room
temperature. The cells were incubated overnight at 4 °C
with anti-EGFR antibody and anti-PD-L1 antibody [28-8]
(Alexa Fluor® 647) (Abcam ab209960) 1/100 dilution.
Nuclear DNA was visualized with DAPI. Rabbit IgG
monoclonal isotype control (Alexa Fluor®647)
(ab199093) was used to identify nonspecific binding.
Cells were imaged on the Olympus IX3 inverted
microscope.
Discussion and conclusions
The predictive value of PD-L1 expression in primary tis-
sues is limited [9]. Furthermore, there is weak correl-
ation between matched primary tumour and distant
metastasis, suggesting that primary tumour is not an ad-
equate surrogate for determining PD-L1 expression at
metastatic sites [21]. Importantly, this highlights the fact
that a single core biopsy may not suffice to determine
tumour PD-L1 expression [9]. The FDA-approved Cell-
Search technology has shown clinical significance of
Fig. 4 CTC clusters detected after enrichment using spiral microfluidics. a 200X magnification composite PD-L1/DAPI (b) CTC cluster magnified
(1000X) showing individual and composite images for DAPI, EGFR, PD-L1 and PD-L1/DAPI. c 1000X magnification of a further CTC cluster present
in the same patient characterized for the same cellular markers. Scale bar represents 100 μm
Fig. 5 Range of expression of PD-L1 across 5 HNC cell lines (FaDu, SCC25, CAL27, SCC15, 93-Vu-147 T), negative control (K562) and patient
sample (HNC01)
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EpCAM-positive CTCs [22]. However, there has been a
shift in the field to maker-independent technologies to
capture a greater proportion of CTCs in circulation in
an unbiased fashion [18, 23]. By the use of established
[9, 22] and spiral microfluidics technology [17, 24] this
study aimed to capture the tumour cells in circulation of
this patient and characterize the PD-L1 expression.
The patient presented with CTCs by enrichment using
both CellSearch and spiral technologies. Importantly, the
spiral technology was able to enrich for CTC clusters
which are rarely detectable by CellSearch [25]. These
microemboli/tumour cell clusters have shown an in-
creased metastatic potential compared to single cells
[26, 27]. Moreover, the cluster had a mid-high PD-L1 ex-
pression compared to the panel of known head and neck
cancer cell lines. The PD-L1 + CTCs indicate that the
patient had tumour cells in circulation with the capacity
to block the immune system. These could be a potential
targets for PD-L1 therapies [9]. The development of an
immune-score is desirable for metastatic HNC patients.
In the 2016 AACR meeting, in locally advanced HNC
patients, PD-L1+ CTCs were associated with shorter
progression free survival (PFS) and overall survival (OS),
and were proposed to “select and monitor patients for
PD-1 checkpoint inhibitors” [28, 29]. These studies as
well as this study, demonstrate that PD-L1 is expressed
in HNSCC tumours and CTCs and may contribute to
the tumours ability to evade the immune system. More-
over, that PD-L1 may be used as a biomarker for pre-
dicting responders from non-responders in lieu of the
cost burden of such therapies.
This case report highlights the potential of using of
CTCs to (i) identify patients ‘at-risk’ of developing metas-
tasis (ii) identifying HNC patients that are likely to benefit
from anti PD-L1 therapy and (iii) the development of a
CTC PD-L1 immune-score for HNC. Further studies are
warranted comparing patient tumour and CTC PD-L1 ex-
pression to develop predictive biomarkers.
Additional file
Additional file 1: Fig. S1. HNSCC cell lines (FaDu) immunofluorescent
staining with DAPI (Blue), PD-L1 (Red). Scale bar represents 10 μm. Fig. S2
Rabbit IgG monoclonal Isotype control (AlexaFluor 647) (ab199093). Scale
bar represents 10 μm. Fig. S3 DAPI and PD-L1 staining on HNSCC cell line
(SCC15) spiked into Normal healthy blood and sorted on the spiral chip
(CTC outlet). White arrows indicate leukocytes in the background of spiked
tumour cells. Scale bar represents 10 μm. Fig. S4 PD-L1 staining of white
blood cells in the waste channel of the spiral chip. Scale bar represents 10 μm.
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